Pictet-spengler ligation for protein chemical modification
US-2015291699-A1 · Oct 15, 2015 · US
Method for removing acetaldehyde
US11964020B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11964020-B2 |
| Application number | US-202217838638-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 13, 2022 |
| Priority date | Dec 4, 2014 |
| Publication date | Apr 23, 2024 |
| Grant date | Apr 23, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.
First claim
Opening claim text (preview).
The invention claimed is: 1. A radioactive pharmaceutical composition comprising an aldehyde scavenger, a radioactive pharmaceutical, and a pharmaceutically acceptable solvent, wherein the aldehyde scavenger is any molecule that has an amino-oxy terminus, and the radioactive pharmaceutical is 2. The composition according to claim 1 , wherein the radioactive pharmaceutical is [ 18 F]flutemetamol. 3. The composition according to claim 1 , wherein the aldehyde scavenger has the following structure: 4. The composition according to claim 1 , wherein the radioactive pharmaceutical is a positron emission tomography (PET) tracer. 5. The composition according to claim 1 , wherein the radioactive pharmaceutical is a 18 F PET tracer. 6. The composition according to claim 1 , wherein the solvent comprises an alcohol. 7. The composition according to claim 6 , wherein said alcohol is ethanol, isopropanol or a bioalcohol. 8. The composition according to claim 6 , wherein said alcohol is ethanol. 9. The composition according to claim 2 , wherein the aldehyde scavenger has the following structure: 10. The composition according to claim 2 , wherein the radioactive pharmaceutical is a positron emission tomography (PET) tracer. 11. The composition according to claim 3 , wherein the radioactive pharmaceutical is a positron emission tomography (PET) tracer. 12. The composition according to claim 3 , wherein the radioactive pharmaceutical is a 18 F PET tracer. 13. A The composition according to claim 3 , wherein the solvent comprises an alcohol. 14. The composition according to claim 13 , wherein said alcohol is ethanol.
Assignees
Inventors
Classifications
- A61K47/42Primary
Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) · CPC title
- A61K47/64Primary
Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil · CPC title
- A61K51/0453Primary
having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole · CPC title
- A61K51/082Primary
the peptide being a RGD-containing peptide · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11964020B2 cover?
- A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.
- Who is the assignee on this patent?
- Ge Healthcare Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K47/42. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).